Cancer Immunotherapy and Nanomedicine

Purpose: The immune system can recognise and kill pre-cancer and cancer cells, but surviving tumour cells learn to escape immune surveillance after immunoselection. Cancer immunotherapy aims to overcome these escape mechanisms. Nanomedicine offers tools—nanodiagnostics and nanobiopharmaceuticals—to deliver antigens, adjuvants, cytokines, and nucleic acids, and to target immune cells or the tumour microenvironment, potentially improving the efficacy of cancer immunotherapy. ---

Hypothesis: No formal hypothesis is tested; the central thesis is: if nanocarriers can deliver tumour antigens, adjuvants, cytokines, and immunomodulatory nucleic acids to appropriate immune cells and compartments—and can also target or reprogram the immunosuppressive tumour microenvironment—then nanomedicine can enhance cancer immunotherapy and overcome tumour immunoediting. ---

Aims: - Discuss the relationships between the tumour and the immune system. - Review strategies used to eliminate tumours using nanomedicine. - Cover nonspecific immune activation agents (cytokines, interferons, TLR agonists) and tumour-specific immune activation strategies. - Describe therapeutic cancer vaccine types (peptide/protein, DNA, DC-based, nanoparticle-based) and adjuvants. - Outline drawbacks of nanomedicine in immune response and immunotherapy, and current/future developments. ---

Delivery system: Nanocarrier platforms: - Liposomes (including cationic DOTAP liposomes; LPD = lipid–polycation–DNA complexes; liposome–polycation–DNA particles) - Polymeric nanoparticles: PLGA, chitosan, poly(glutamic acid) (PGA), magnetic nanoparticles - PEGylated nanoparticles (PEG grafting to reduce macrophage uptake and increase circulation half-life) - Oil-in-water emulsions, mineral salts, aluminium compounds, microspheres, attenuated viruses, cells - Nanoparticle-based vaccines with three design parts: antigen, targeting ligand, delivery material Payloads: - Tumour antigens: proteins, peptides, carbohydrates, glycoproteins, gangliosides, DNA/RNA encoding cancer-associated antigens - Cytokines: IL-2, IL-12, IL-18, IL-21, GM-CSF, IFN-α/β/γ - TLR agonists: CpG ODN (TLR9), MPL, imiquimod (TLR7) - Adjuvants: alum, AS04, MF59, incomplete Freund’s adjuvant (IFA), DOTAP, QS21 - Nucleic acids: plasmid DNA vaccines, siRNA, CpG ODNs (e.g., G3139) - Bispecific antibodies (bAbs) and antibodies against immune suppressors (anti-CD25, anti-CTLA-4, anti-Bv8) Targeting ligands: - DC-specific antibodies (e.g., anti-lectin DEC-205) - TLR ligands (e.g., monophosphoryl lipid A) ---

Approach: Review of preclinical and clinical literature. Model systems include: - In vitro: DC uptake and maturation assays, antigen presentation, CTL induction. - In vivo: Mouse tumour models (e.g., CT26, B16 melanoma, ID8 ovarian, HER-2/neu, C3H/HeN melanoma), tumour challenge/rechallenge, metastasis models. - Clinical: Phase I/II/III trials in melanoma, renal cell carcinoma, ovarian cancer, prostate cancer, cervical cancer, non-small-cell lung cancer, breast cancer, B-cell lymphoma, glioblastoma. - Disease context: Cancer immunotherapy, including prophylactic vaccines (HBV, HPV) and therapeutic vaccines. ---

Key methods: Techniques highlighted across cited studies: - ELISA for cytokines (IFN-γ, IL-2, IL-4, IL-10, TNF-α, IL-12) - Flow cytometry for T cell subsets, Tregs, MDSCs, DC maturation markers (MHC II, CD86) - Tumour growth inhibition and survival analysis - CTL cytotoxicity assays - Spleen size and lymphocyte proliferation - Antigen-specific antibody and IgG titers - Biodistribution and pharmacokinetics of nanoparticles - Immunohistochemistry and histology ---

Key results: - G3139-LNP (CpG ODN against Bcl-2 encapsulated in lipid nanoparticles): enhanced IFN-γ, IL-2, IL-4, and IL-10 by ~4-fold; significantly enlarged spleen; inhibited tumour growth by >50%; prolonged host survival by 245%. - IL-18 + liposomal doxorubicin combination: 22% of mice remained tumour-free for 6 months vs 0% for either monotherapy in an ID8 ovarian tumour model. - Sipuleucel-T (Provenge®): first FDA-approved cancer therapeutic vaccine (April 2010); in phase III, extended median survival of metastatic castrate-resistant prostate cancer patients by 4.1 months vs placebo (n=341 vs n=171). - DOTAP/E7 liposomes: induced antigen-specific CTL activity, increased CD4+ T cells, decreased Tregs, and caused complete tumour regression in treated mice (tumour injected 6 days before treatment). Low TNF-α expression, but overdose caused massive ROS and DC apoptosis. - LPD/E7: taken up by ~50% DCs, ~50% NK cells, and ~30% macrophages in draining lymph nodes after subcutaneous footpad injection; generated antigen-specific CTL responses and complete tumour regression. - Peptide/protein vaccines: safe but low immunogenicity; require adjuvants/cytokines. - DNA vaccines: induce antibody and CTL responses; weak immunogenicity, require repeated/high-dose administration; concerns about oncogene transformation. - DC vaccines: disappointing in solid tumours; Sipuleucel-T is the exception. - Adjuvants: alum and AS04 are the only FDA-approved adjuvants for human use in the USA; AS04 and MF59 licensed in Europe. ---

Interpretation: The authors claim that nanomedicine holds great promise for cancer immunotherapy by improving delivery of immunostimulatory agents, enhancing vaccine efficacy, and overcoming tumour immunoediting. They emphasise that combination therapies—vaccines with chemotherapy, checkpoint blockade, or cytokines—and targeting of the tumour microenvironment (Tregs, MDSCs, TGF-β) are important future directions. They also note that safety, immunogenicity, and manufacturing challenges must be addressed before clinical translation. ---

Limitations: - Protein and DNA vaccines may cause cell transformation. - Viral-based vaccines carry risks of genetic recombination, chromosome integration, virulence, and pre-existing immunity. - NP-based vaccines present potential toxicity; anti-liposome or anti-PEG antibody responses have been observed. - Cancer vaccines can cause flu-like symptoms, inflammation, and rarely asthma, autoimmune disease, or severe hypersensitivity. - Tumour microenvironment changes (MHC loss, Treg/MDSC increases, TGF-β upregulation) can offset vaccine efficacy. - DC vaccines have been largely disappointing in clinical trials. - Stimuvax® trials were temporarily closed in 2010 due to an unexpected serious adverse reaction. - IL-2 therapy has dose-related morbidity and can expand Tregs. - DOTAP overdose can induce ROS and DC apoptosis. - LPD may cause systemic toxicity due to high TNF-α induction. - GMP standardisation and cost issues remain for clinical translation.